Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEST3: Neoadjuvant Botensilimab and Balstilimab in Resectable Colon Cancer
NCT07595874Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab, balstilimab in colorectal cancer (CRC), sponsored by City of Hope. Started Jul 2026; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07595874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595874.